Recent Updates
Recently added Catalysts
EBS Positive Sentiment

Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08

Thursday, March 20, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Emergent BioSolutions Inc. announced the granting of an equity award to a newly hired employee under its 2023 Inducement Plan. The award consists of restricted stock units and stock options totaling 72,882 shares of common stock, which will vest fully on March 15, 2026, contingent on the employee's continuous service. This decision reflects the company's strategy to attract and retain talented individuals in the public health sector.
Price reaction · baseline $5.84 (2025-03-19 close) · hit after-hours · clean, no other EBS news in the window
day 0 close · peak
-1.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • Equity award demonstrates commitment to attracting talent.
  • Employee granted a substantial number of shares, indicating confidence in growth.
  • Award aligns with company's 2023 Inducement Plan, showcasing strategic planning.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+70%
120-day peak, hindsight
Typical move
8%
average across 2 past catalysts
Lead asset
FLU-IGIV
Phase 2 · Influenza A H3N2

Full Press Release Details

GAITHERSBURG, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a leading public health company that delivers protective and life-saving solutions to communities across the world, today announced that its Compensation Committee has granted an equity award to a newly hired employee under its 2023 Inducement Plan (the "Inducement Plan").
The employee will receive an award of restricted stock units and stock options representing 72,882 shares of Emergent common stock (the “Equity Award”) as of March 15, 2025 in reliance on the employment inducement award exception to New York Stock Exchange Listing Rule 303A.08. The Equity Award will be fully vested on March 15, 2026, subject to the employee’s continuous service through the vesting date.
About Emergent BioSolutions
Executive Vice President, CFO

Frequently Asked Questions

What is the purpose of Emergent BioSolutions' Inducement Plan?

The Inducement Plan aims to grant equity awards to attract new employees.

How many shares are included in the equity award?

The equity award includes 72,882 shares of Emergent common stock.

When will the equity award fully vest?

The equity award will fully vest on March 15, 2026.

What is required for the equity award to vest?

The employee must maintain continuous service until the vesting date.

Which stock exchange rule is related to this equity award?

It relies on the NYSE Listing Rule 303A.08 for inducement awards.

ShareAdd on Google
Tags: EBS Viatris Investor Conferences Healthcare Emergent BioSolutions equity grant new hire NYSE
Last updated: Mar 20, 2025

Biotech snapshot

Cash runway
$141M liquidity · $0M/mo burn
Low dilution risk
Lead asset
FLU-IGIVPhase 2
Influenza A H3N2 →

Catalyst track record

+70%
best trade around EBS's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for EBS.

See every catalyst's timing & PoA →